These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
2195 related items for PubMed ID: 28851809
1. Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption. Johansen AK, Molenaar B, Versteeg D, Leitoguinho AR, Demkes C, Spanjaard B, de Ruiter H, Akbari Moqadam F, Kooijman L, Zentilin L, Giacca M, van Rooij E. Circ Res; 2017 Oct 27; 121(10):1168-1181. PubMed ID: 28851809 [Abstract] [Full Text] [Related]
2. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice. El Refaey M, Xu L, Gao Y, Canan BD, Adesanya TMA, Warner SC, Akagi K, Symer DE, Mohler PJ, Ma J, Janssen PML, Han R. Circ Res; 2017 Sep 29; 121(8):923-929. PubMed ID: 28790199 [Abstract] [Full Text] [Related]
3. CRISPR-Mediated Activation of Endogenous Gene Expression in the Postnatal Heart. Schoger E, Carroll KJ, Iyer LM, McAnally JR, Tan W, Liu N, Noack C, Shomroni O, Salinas G, Groß J, Herzog N, Doroudgar S, Bassel-Duby R, Zimmermann WH, Zelarayán LC. Circ Res; 2020 Jan 03; 126(1):6-24. PubMed ID: 31730408 [Abstract] [Full Text] [Related]
4. A mouse model for adult cardiac-specific gene deletion with CRISPR/Cas9. Carroll KJ, Makarewich CA, McAnally J, Anderson DM, Zentilin L, Liu N, Giacca M, Bassel-Duby R, Olson EN. Proc Natl Acad Sci U S A; 2016 Jan 12; 113(2):338-43. PubMed ID: 26719419 [Abstract] [Full Text] [Related]
5. In Vivo Ryr2 Editing Corrects Catecholaminergic Polymorphic Ventricular Tachycardia. Pan X, Philippen L, Lahiri SK, Lee C, Park SH, Word TA, Li N, Jarrett KE, Gupta R, Reynolds JO, Lin J, Bao G, Lagor WR, Wehrens XHT. Circ Res; 2018 Sep 28; 123(8):953-963. PubMed ID: 30355031 [Abstract] [Full Text] [Related]
7. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure. Soriano V. AIDS Rev; 2017 Sep 28; 19(3):167-172. PubMed ID: 29019352 [Abstract] [Full Text] [Related]
10. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1. Marsh S, Hanson B, Wood MJA, Varela MA, Roberts TC. Mol Ther; 2020 Dec 02; 28(12):2527-2539. PubMed ID: 33171139 [Abstract] [Full Text] [Related]
11. Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field. He ZY, Men K, Qin Z, Yang Y, Xu T, Wei YQ. Sci China Life Sci; 2017 May 02; 60(5):458-467. PubMed ID: 28527117 [Abstract] [Full Text] [Related]
13. Design of a generic CRISPR-Cas9 approach using the same sgRNA to perform gene editing at distinct loci. Najah S, Saulnier C, Pernodet JL, Bury-Moné S. BMC Biotechnol; 2019 Mar 20; 19(1):18. PubMed ID: 30894153 [Abstract] [Full Text] [Related]
14. CRISPR/Cas9-Mediated Genome Editing in Epstein-Barr Virus-Transformed Lymphoblastoid B-Cell Lines. Jiang S, Wang LW, Walsh MJ, Trudeau SJ, Gerdt C, Zhao B, Gewurz BE. Curr Protoc Mol Biol; 2018 Jan 16; 121():31.12.1-31.12.23. PubMed ID: 29337376 [Abstract] [Full Text] [Related]